Exploring HER2 testing in high-grade ovarian cancer
Part of Cancer, Women’s health & pregnancy clinical trials.
This study looks at how to best detect the HER2 protein in high-grade serous ovarian cancer. The goal is to improve treatment choices for people with this type of cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have high-grade serous adenocarcinoma of the ovary (a specific type of ovarian cancer).
- Tumor tissue samples from a biopsy or surgery are available and were collected in the last 5 years.
- Your cancer was at stage II or higher according to the FIGO system (the cancer had spread beyond the ovary).
- Your medical records and follow-up information are complete.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This study looks at why some high-grade ovarian cancers stop responding to standard chemotherapy. It aims to find ways to overcome that resistance, which may help improve treatment outcomes.
This trial uses a special imaging technique to study high-grade serous ovarian cancer. It aims to better understand the tumor to improve treatment. If you have advanced ovarian cancer and are scheduled for surgery, you may be eligible.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This study looks at a protein called DHODH in tumor tissue from people with high-grade serous ovarian cancer. It compares DHODH levels between those who had surgery first and those who had chemotherapy first, to see if it relates to treatment outcomes.
This study looks at how women with advanced ovarian cancer respond to treatments based on whether their tumors have a specific DNA repair problem called homologous recombination deficiency (HRD). It aims to understand which treatments work best for different HRD test results.
Hear when a new Exploring HER2 Positive Diagnostic Criteria in High-grade Serous Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.